Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06857851

Optimizing Deep Brain Stimulation to Improve Visuomotor Function in Parkinson's Disease

Inability to align and refocus the eyes on the objects at different depths, i.e., vergence impairment and strabismus, frequently affects the quality of life in patients with Parkinson's disease. The investigators study aims to understand the location-specific effects of subthalamic region deep brain stimulation on vergence and strabismus by integrating the patient-specific deep brain stimulation models and high-resolution eye-tracking measures. The knowledge gained will allow the investigators to find the most beneficial stimulation location and parameters for improving binocular coordination, strabismus, and vergence while preserving the ability to treat motor symptoms in Parkinson's disease.

Recruiting

Interested in participating?

Request Info

Key information

Sex eligibility

All sexes

Study type

Observational

Primary location

Louis Stokes VA Medical Center, Cleveland, OH

Cleveland, Ohio, 44106-1702, United States

Location status: Recruiting

Location contact

Aasef G Shaikh, MD PhD

CONTACT

[email protected]

(216) 791-3800 ext. 60000

Aasef G. Shaikh, MD PhD

PRINCIPAL_INVESTIGATOR

Cheryl Dudek

CONTACT

[email protected]

216-679-3800

About this study

The victims of very common condition Parkinson's disease (PD) are known to have tremor, rigidity, and slow movements. PD, in addition to its effects on human movements, also affects many other aspect of the brain's function. Impairment of vision is frequently seen in PD. These patients have difficulties with holding their eyes steady at a given point, seamlessly look around and read, and refocus their eyes from one image to the other while looking at objects that are at different depths. About third of the PD patients have problems coordinating the movement of two eyes together, i.e., abnormal vergence and strabismus. Latter results in disabling double vision and abnormal depth perception. Most treatment options available to PD patients are limited to their effects on tremor, stiffness, and slowness - their effects on visual function is very limited. Eye surgeries are not ideal treatment strategies for these conditions given constantly changing state of the PD brain due to its degenerative nature. Cutting edge deep brain stimulation (DBS) surgery has variable effects on the eye movements and vergence function and strabismus in PD. The goal of the investigators research program is to identify the best possible therapeutic strategy using DBS to improve vergence eye movements and strabismus in PD while continuing to offer its other benefits. The investigators multidisciplinary program has two aspects. One part of the study will examine the effects of DBS on vergence abnormalities and strabismus affecting their ability to focus at various depths. Using state of art, high-resolution, research grade ophthalmic equipment the investigators will examine fine details of how DBS alters the patients' ability to refocus and how it changes the alignment between the two eyes that can cause double vision and abnormal depth perception. Once the investigators identify these characteristic changes, the investigators will correlate them with the stimulated anatomical location within the same patient's brain determined using combination of novel computer simulations of DBS and the patient's own MRI. The knowledge gained will allow the investigators to find the ideal stimulation locations that is most beneficial to the patient for improvement in vision while continuing to offer benefits for tremor, rigidity, and slow movements.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Parkinson's disease with bilateral STN DBS
  • Availability of pre-operative MR images (with a T1-weighted, gradient-echo sequence) and ability to get post-operative MRI or CT scans
  • Hoehn and Yahr stage 2-4 when off medication, and a stable antiparkinsonian medication regimen and DBS parameter settings

Exclusion criteria

  • Previous surgical therapy for Parkinson's disease (other than DBS)
  • Dementia
  • Clinically significant untreated depression or anxiety
  • Clinical features suggestive of atypical parkinsonism

Treatment and study plan

Primary outcomes

  1. Eye alignment - vergence gain

    Time frame: One month

    The investigators will measure vergence gain as one outcome measure. This measure will be calculated by measuring ratio of observed versus expected difference between the horizontal angular positions of the right and left eye as participants move gaze from far to near or vice versa.

  2. Strabismus

    Time frame: One month

    The investigators will measure difference in position of right versus left eye as participants hold gaze on object of interest.

Study contacts

Contact information is provided by the study sponsor or research team.

Aasef G Shaikh, MD PhD

CONTACT

[email protected]

(216) 791-3800 ext. 60000

Cheryl Dudek

CONTACT

[email protected]

(216) 679-3800

Sponsors and collaborators

Lead sponsor

VA Office of Research and Development

Fed

Registry information

Acronym: DBS strabismus

Important dates

Study start
2026
Primary completion
2029
Study completion
2029
First posted
Mar 4, 2025
Registry last updated
Jul 7, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.